leisure time -WSS

leisure time

author：comprehensive 2025-10-01 02:13:19 - browse：3

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Ukraine and a new approach to mental health in war

Wikipedia

WSS

Why Novartis is going to walk from its acquisition of MorphoSys

Readout LOUD: Venture capital, Gilead, and more M&A

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

CDC's new outbreak response network to include Northeastern

Microbiome research is starting to find links to chronic diseases

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

hotspot

leisure time

focus

Activists slam private health insurers over coverage restrictions

Medicare Advantage plans can’t deny care with AI, CMS warns

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why CTE doesn’t keep Americans from enjoying the Super Bowl

United colonoscopy coverage change 'may cost lives,' doctors say

Experts study whether long Covid risk adds up with each reinfection

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: possible new ALS drug, artificial wombs

In age of alternative facts, a scholarly course on calling out crap

Medicare Advantage plans can’t deny care with AI, CMS warns

leisure time

Senate HELP committee spars over health care workforce policies

Top private equity targets in 2023: cardiology, clinical trials, lasers

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Medical student insurance fails on mental health care coverage

Problems with a popular proposal to regulate AI in health care

focus

entertainment

Wikipedia

leisure time